Our purpose was to describe the prevalence and predictors of symptom and function clusters related to physical, emotional, and social components of general health-related quality of life (HRQOL) in a population-based sample of prostate cancer (PCa) survivors.
Participants (N = 1,162) completed a baseline survey at a median of 9 months after diagnosis to ascertain the co-occurrence of eight symptom and functional domains that are common across all cancers and not treatment-specific. We used latent profile analysis (LPA) to identify subgroup profiles of survivors with low, moderate, or high HRQOL levels. Multinomial logistic regression models were used to identify clinical and sociodemographic factors associated with survivors' membership in the low versus moderate or high HRQOL profile.
The LPA identified 16% of survivors who were categorized in the low HRQOL profile at baseline, indicative of the highest symptom burden and lowest functioning. Factors related to survivors' membership in the low versus higher HRQOL profile groups included less than age 65 years at diagnosis, identifying as non-Hispanic Black race, not working, being a former versus never smoker, systemic therapy, less companionship, more comorbidities, lower health care financial well-being, or less spirituality. Several factors remained associated with remaining in the low versus higher HRQOL profiles on the follow-up survey (n = 699), including younger age, Black race, comorbidity, and lower financial and spiritual well-being.
About one of six PCa survivors experienced elevated physical and psychosocial symptoms that were independent of local curative therapy, but with younger age, race, comorbidity, and lower financial and spiritual well-being as stable risk factors for poor HRQOL over time.
JCO oncology practice. 2024 Mar 11 [Epub ahead of print]
Arnold L Potosky, Jaeil Ahn, Yi Xia, Li Lin, Ronald C Chen, Kristi D Graves, Wei Pan, Jane M Fall-Dickson, Theresa H M Keegan, Lisa E Paddock, Xiao-Cheng Wu, Anshu Shrestha, Bryce B Reeve
Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC., Department of Biostatistics, Bioinformatics and Biomathematics, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC., Department of Population Health Sciences, Center for Health Measurement, Duke University School of Medicine, Durham, NC., Department of Radiation Oncology, University of Kansas School of Medicine, Kansas City, KS., Department of Population Health Sciences, Duke University School of Nursing, Duke University School of Medicine, Durham, NC., Georgetown University School of Nursing, Georgetown University Medical Center, Washington, DC., Division of Hematology and Oncology, Department of Internal Medicine, University of California-Davis Comprehensive Cancer Center, Sacramento, CA., Rutgers School of Public Health and Cancer Institute of New Jersey, New Brunswick, NJ., Louisiana State University Health Sciences Center School of Public Health, Louisiana Tumor Registry, New Orleans, LA., Public Health Institute, Cancer Registry of Greater California, Sacramento, CA.